30 completed, 3 unknown, 1 active not recruiting, 1 terminated. 35 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Completed 30, Unknown 3, Active not recruiting 1, Terminated 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
Follow Meningitis, Meningococcal: new trials by email Literature Review of Meningitis, Meningococcal trials Research Report on Meningitis, Meningococcal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, ACYW135 Meningococcal Polysaccharide Vaccine - Meningococcal Meningitis | Phase 2 | Unknown | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | 1200 | 2024-03-20 | 2024-03-29 |
| Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents MenABCWY vaccine, Placebo - Meningitis, Meningococcal | Phase 2 | Active not recruiting | GlaxoSmithKline | 305 | 2021-11-18 | 2026-09-28 |
| Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 2 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 720 | 2018-12-21 | 2022-02-25 |
| Conjugate Vaccine Against Meningococcus C a Brazilian Project MenCC-BIO Vaccine, Combined - CRM197 - Serogroup C Meningococcal Meningitis | Phase 2 / Phase 3 | Unknown | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 1644 | 2018-09-25 | 2018-10-10 |
| A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age MenACWY liquid, MenACWY - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1707 | 2018-08-30 | 2021-02-17 |
| Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years MenABCWY vaccine, rMenB+OMV NZ (Bexsero) vaccine, MenACWY (Menveo) vaccine - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 520 | 2018-07-09 | 2020-02-12 |
| Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds Non-adjuvanted study formulation NmCV-5, Adjuvanted study formulation NmCV-5, Menactra - Meningitis, Meningococcal | Phase 2 | Completed | Serum Institute of India Pvt. Ltd. | 375 | 2017-11-15 | 2025-05-25 |
| Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free), Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant) - Meningitis, Meningococcal Meningitis | Phase 1 / Phase 2 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 360 | 2016-08-01 | 2016-09-29 |
| Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 224 | 2016-06-06 | 2018-01-08 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 188 | 2015-03-31 | 2022-04-04 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1715 | 2014-07-22 | 2022-04-04 |
| Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine Test Vaccine, US Licensed Vaccine - Meningococcal Meningitis, Meningococcal Infections | Phase 2 | Completed | JN-International Medical Corporation | 525 | 2013-07-01 | 2015-04-23 |
| Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age rLP2086 - Meningitis, Meningococcal, Serogroup B | Phase 2 | Completed | Pfizer | 13 | 2013-02-01 | 2018-12-20 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 301 | 2012-11-12 | 2022-04-04 |
| Comparison of Two Meningococcal ACWY Conjugate Vaccines Menveo, MenACWY-TT - Meningococcal Meningitis | Phase 2 / Phase 3 | Completed | Public Health England | 91 | 2012-06-01 | 2020-10-01 |
| Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers MenC-CRM LIQ, MenC-CRM ROS, MenC-CRM EMV - Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Completed | Novartis | 992 | 2011-09-01 | 2017-04-25 |
| Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap - Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Completed | Novartis Vaccines | 440 | 2011-07-01 | 2014-11-19 |
| Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents Meningococcal Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Completed | Novartis Vaccines | 495 | 2010-12-01 | 2011-10-24 |
| Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi | 139 | 2010-11-01 | 2012-06-25 |
| Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 No Vaccine, rMenB+OMV-NZ - Meningococcal Disease, Meningococcal Meningitis | Phase 2 / Phase 3 | Completed | Novartis Vaccines | 817 | 2010-08-01 | 2018-06-15 |
Showing 20 of 35. Sign in to see all of them.
Meningococcal Infections (18) · Meningitis (17) · Central Nervous System Infections (1) · Diphtheria (1) · Poliomyelitis (1) · Tetanus (1) · Whooping Cough (1)
Bacterial Infections (35) · Bacterial Infections and Mycoses (35) · Central Nervous System Bacterial Infections (35) · Central Nervous System Diseases (35) · Gram-Negative Bacterial Infections (35) · Infections (35) · Meningitis, Bacterial (35) · Neisseriaceae Infections (35) · Nervous System Diseases (35) · Neuroinflammatory Diseases (35) · Central Nervous System Infections (34) · Meningitis (18) · Meningococcal Infections (17) · Actinomycetales Infections (1) · Bordetella Infections (1)
Meningococcal Vaccines (11) · 4CMenB vaccine (4) · Vaccines (3) · MenACWY (2) · Antipyretics (1) · Blood Specimen Collection (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · HibTITER protein, Haemophilus influenzae (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · MenACWY-CRM vaccine (1) · MenC-CRM vaccine (1) · Papillomavirus Vaccines (1) · Saline Solution (1)
Novartis Vaccines (9) · Sanofi Pasteur, a Sanofi Company (5) · GlaxoSmithKline (4) · Pfizer (3) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · Sanofi (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Aimei Vacin BioPharm (Zhejiang) Co., Ltd. (1) · Armauer Hansen Research Institute, Ethiopia (1) · JN-International Medical Corporation (1) · Novartis (1) · Prof. Elizabeth Miller (1) · Public Health England (1) · Serum Institute of India Pvt. Ltd. (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1)
United States (11) · Chile (4) · Spain (4) · China (3) · Czechia (3) · Finland (3) · Poland (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Colombia (2) · Germany (2) · Italy (2) · Panama (2) · Argentina (1)
Abraham Aseffa Aseffa, M.D, PhD (1) · Ahmed Bedru Omer, M.D,Pediatrician (1) · Alberto Yataco, MD (1) · Elizabeth Miller, MD (1) · Francisco Diaz-Mitoma, Dr. (1) · Jeffrey E Atkinson, MD (1) · Lin Du (1) · Myron I Murdock, MD (1)
PMID 35164991, PMID 17548138, PMID 21177912, PMID 22569484, PMID 23114372, PMID 23352429, PMID 25077420, PMID 25424810, PMID 25969894, PMID 26075813, PMID 26135245, PMID 26756390, PMID 27745812, PMID 32209248, PMID 32233959, PMID 32233961, PMID 32681472, PMID 33020485, PMID 34077644, PMID 34787449, PMID 35257644, PMID 36369456, PMID 40043411
2008 (2), 2009 (2), 2017 (2), 2014 (1)